| dc.contributor.author | López Cano, Carolina | |
| dc.contributor.author | Ciudin, Andreea | |
| dc.contributor.author | Sánchez Peña, Enric | |
| dc.contributor.author | Tinahones, Francisco José | |
| dc.contributor.author | Barbé Illa, Ferran | |
| dc.contributor.author | Dalmases, Mireia | |
| dc.contributor.author | García Ramírez, Marta | |
| dc.contributor.author | Soto, Alfonso | |
| dc.contributor.author | Michela Gaeta, Anna | |
| dc.contributor.author | Pellitero, Silvia | |
| dc.contributor.author | Martí, Raquel | |
| dc.contributor.author | Hernández, Cristina | |
| dc.contributor.author | Simó, Rafael | |
| dc.contributor.author | Lecube Torelló, Albert | |
| dc.date.accessioned | 2022-03-03T08:59:31Z | |
| dc.date.available | 2022-03-03T08:59:31Z | |
| dc.date.issued | 2022 | |
| dc.identifier.issn | 0012-1797 | |
| dc.identifier.issn | 1939-327X | |
| dc.identifier.uri | http://hdl.handle.net/10459.1/73145 | |
| dc.description.abstract | To evaluate the effect of liraglutide, a glucagon-like peptide 1 receptor agonist, on pulmonary function and serum levels of surfactant protein D (SP-D) in type 2 diabetes. A double-blind, randomized, crossover, placebo-controlled clinical trial comprising 76 patients with a baseline forced expiratory volume in 1 s <90% of that predicted. Liraglutide was administered for 7 weeks (2 weeks of titration plus 5 weeks at 1.8 mg daily). This short duration was intentional to minimize weight loss as a potential confounding factor. Serum level of SP-D was used as a biomarker of alveolar-capillary barrier integrity. Liraglutide exerted a positive impact on forced vital capacity (FVC) in comparison with placebo (ΔFVC 5.2% of predicted [from 0.8 to 9.6]; P = 0.009). No differences in the other pulmonary variables were observed. Participants under liraglutide treatment also experienced a decrease in serum SP-D (P = 0.038). The absolute change in FVC correlated with final serum SP-D in participants receiving liraglutide (r = −0.313, P = 0.036). Stepwise multivariate regression analysis showed that final serum SP-D independently predicted changes in FVC. In conclusion, liraglutide increased FVC in patients with type 2 diabetes. This effect was associated with a significant decrease of circulating SP-D, thus pointing to a beneficial effect in the alveolar-capillary function. | ca_ES |
| dc.description.sponsorship | CIBERDEM and CIBEROBN are initiatives of Instituto de Salud Carlos III (PI 15/00260 and PI 18/00964). The drugs under study were supplied by Novo Nordisk at the request of the sponsor of the study expressly for the clinical trial, with Novo Nordisk taking responsibility for the manufacture, packaging, and labeling. | ca_ES |
| dc.language.iso | eng | ca_ES |
| dc.publisher | American Diabetes Association | ca_ES |
| dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.2337/db21-0688 | ca_ES |
| dc.relation.ispartof | Diabetes 2022, vol. 71, núm. 2, p. 315–320 | ca_ES |
| dc.rights | (c) American Diabetes Association, 2021 | ca_ES |
| dc.title | Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Study | ca_ES |
| dc.type | info:eu-repo/semantics/article | ca_ES |
| dc.identifier.idgrec | 031771 | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | ca_ES |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | ca_ES |
| dc.identifier.doi | https://doi.org/10.2337/db21-0688 | |
